A	O
major	O
inconvenience	O
for	O
the	DATE
future	DATE
clinical	O
development	O
of	O
betulinic	O
acidand	O
analogues	O
resides	O
in	O
their	O
poor	O
solubility	O
in	O
aqueous	O
media	O
such	O
as	O
bloodserum	O
and	O
polar	O
solvents	O
used	O
for	O
bioassays	O
.	O
To	O
circumvent	O
this	O
problem	O
ofhydrosolubility	O
and	O
to	O
enhance	O
pharmacological	O
properties	O
,	O
many	O
derivativeswere	O
synthesized	O
and	O
evaluated	O
for	O
cytotoxic	O
activity	O
.	O
One	NUMBER
study	O
showed	O
C-20modifications	O
involve	O
the	O
loss	O
of	O
cytotoxicity	O
.	O
Another	O
study	O
demonstrated	O
theimportance	O
of	O
the	O
presence	O
of	O
the	O
-	O
COOH	O
group	O
,	O
since	O
compounds	O
substituted	O
atthis	O
position	O
,	O
such	O
as	O
lupeol	O
and	O
methyl	O
betulinate	O
,	O
were	O
less	O
active	O
on	O
humanmelanoma	O
than	O
betulinic	O
acid	O
.	O
Moreover	O
,	O
some	O
C-28	MISC
amino	O
acids	O
and	O
C-3phthalates	O
derivatives	O
exhibited	O
higher	O
cytotoxic	O
activity	O
against	O
cancer	CAUSE_OF_DEATH
celllines	O
with	O
improved	O
selective	O
toxicity	O
and	O
water	O
solubility	O
.	O
Chatterjee	PERSON
_	NUMBER
etal	O
.	O
_	O
obtained	O
the	O
28-O-Î²-D-glucopyranoside	O
of	O
betulinic	O
acid	O
by	O
microbialtransformation	O
with	O
_	O
Cunninghamella	O
_	NUMBER
species	O
,	O
while	O
_	NUMBER
Baglin	O
et	O
al.	O
_	O
obtainedit	O
by	O
organic	O
synthesis	O
.	O
This	O
glucoside	O
did	O
not	O
exhibit	O
any	O
significant	O
_	O
invitro	O
_	O
activity	O
on	O
human	O
melanoma	CAUSE_OF_DEATH
and	O
human	O
colorectal	O
adenocarcinoma	O
cell	O
lines	O
,	O
which	O
confirms	O
the	O
importance	O
of	O
the	O
carboxylic	O
acidfunction	O
to	O
preserve	O
the	O
cytotoxicity	O
.	O
Recently	DATE
,	O
Gauthier	PERSON
_	O
et	O
al.	O
_	O
synthesizeda	O
series	O
of	O
3	NUMBER
-	O
_	NUMBER
O	O
_	O
-	O
glycosides	O
of	O
betulinic	O
acid	O
which	O
exhibited	O
a	O
stronglypotent	O
_	O
in	O
vitro	O
_	O
anticancer	O
activity	O
against	O
human	O
cancer	CAUSE_OF_DEATH
cell	O
lines	O
.	O
